1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Asia Pacific RNAi Therapeutics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Asia Pacific RNAi Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Asia Pacific RNAi Therapeutics Market Regional Analysis
6.2 Asia Pacific RNAi Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 Asia Pacific RNAi Therapeutics Market Forecast Analysis
7. Asia Pacific RNAi Therapeutics Market Analysis – by Molecule Type
7.1 Small Interfering RNAs
- 7.1.1 Overview
- 7.1.2 Small Interfering RNAs: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 MicroRNA
- 7.2.1 Overview
- 7.2.2 MicroRNA: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. Asia Pacific RNAi Therapeutics Market Analysis – by Application
8.1 Genetic Disorders
- 8.1.1 Overview
- 8.1.2 Genetic Disorders: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Oncology
- 8.2.1 Overview
- 8.2.2 Oncology: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.3 Neurodegenerative Disorders
- 8.3.1 Overview
- 8.3.2 Neurodegenerative Disorders: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.4 Cardiovascular
- 8.4.1 Overview
- 8.4.2 Cardiovascular: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.5 Respiratory Disorders
- 8.5.1 Overview
- 8.5.2 Respiratory Disorders: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.6 Infectious Diseases
- 8.6.1 Overview
- 8.6.2 Infectious Diseases: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.7 Renal Diseases
- 8.7.1 Overview
- 8.7.2 Renal Diseases: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. Asia Pacific RNAi Therapeutics Market Analysis – by Route of Administration
9.1 Intradermal Injections
- 9.1.1 Overview
- 9.1.2 Intradermal Injections: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Pulmonary Delivery
- 9.2.1 Overview
- 9.2.2 Pulmonary Delivery: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Intravenous Injections
- 9.3.1 Overview
- 9.3.2 Intravenous Injections: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.4 Intraperitoneal Injections
- 9.4.1 Overview
- 9.4.2 Intraperitoneal Injections: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. Asia Pacific RNAi Therapeutics Market Analysis – by End User
10.1 Diagnostic Laboratories
- 10.1.1 Overview
- 10.1.2 Diagnostic Laboratories: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.2 Research and Academic Laboratories
- 10.2.1 Overview
- 10.2.2 Research and Academic Laboratories: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.3 Hospitals
- 10.3.1 Overview
- 10.3.2 Hospitals: Asia Pacific RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
11. Asia Pacific RNAi Therapeutics Market – Asia-Pacific Analysis
11.1 Overview
11.2 Asia-Pacific
- 11.2.1 Asia Pacific RNAi Therapeutics Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 11.2.1.1 Asia Pacific RNAi Therapeutics Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 China:
Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.1.1 China: Asia Pacific RNAi Therapeutics Market Breakdown, by Molecule Type
- 11.2.1.1.2 China: Asia Pacific RNAi Therapeutics Market Breakdown, by Application
- 11.2.1.1.3 China: Asia Pacific RNAi Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.1.4 China: Asia Pacific RNAi Therapeutics Market Breakdown, by End User
- 11.2.1.2 India:
Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.2.1 India: Asia Pacific RNAi Therapeutics Market Breakdown, by Molecule Type
- 11.2.1.2.2 India: Asia Pacific RNAi Therapeutics Market Breakdown, by Application
- 11.2.1.2.3 India: Asia Pacific RNAi Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.2.4 India: Asia Pacific RNAi Therapeutics Market Breakdown, by End User
- 11.2.1.3 Japan:
Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.3.1 Japan: Asia Pacific RNAi Therapeutics Market Breakdown, by Molecule Type
- 11.2.1.3.2 Japan: Asia Pacific RNAi Therapeutics Market Breakdown, by Application
- 11.2.1.3.3 Japan: Asia Pacific RNAi Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.3.4 Japan: Asia Pacific RNAi Therapeutics Market Breakdown, by End User
- 11.2.1.4 Australia:
Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.4.1 Australia: Asia Pacific RNAi Therapeutics Market Breakdown, by Molecule Type
- 11.2.1.4.2 Australia: Asia Pacific RNAi Therapeutics Market Breakdown, by Application
- 11.2.1.4.3 Australia: Asia Pacific RNAi Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.4.4 Australia: Asia Pacific RNAi Therapeutics Market Breakdown, by End User
- 11.2.1.5 Rest of Asia-Pacific :
Asia Pacific RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.5.1 Rest of Asia-Pacific : Asia Pacific RNAi Therapeutics Market Breakdown, by Molecule Type
- 11.2.1.5.2 Rest of Asia-Pacific : Asia Pacific RNAi Therapeutics Market Breakdown, by Application
- 11.2.1.5.3 Rest of Asia-Pacific : Asia Pacific RNAi Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.5.4 Rest of Asia-Pacific : Asia Pacific RNAi Therapeutics Market Breakdown, by End User
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Benitec Biopharma
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Olix Pharmaceuticals, Inc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 GlaxoSmithKline plc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Alnylam Pharmaceuticals, Inc.
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Arrowhead Pharmaceuticals, Inc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Get Free Sample For Asia Pacific RNAi Therapeutics Market
